FATE’s scalable CAR T platform shows promising Phase II lupus nephritis progress
Conference update from FATE highlights a scalable, cost-effective CAR T platform, with Phase II underway for FT819 in lupus nephritis and early results aimed at 30%-40% CRR.
The conference highlighted a scalable, cost-effective CAR T platform, with safety and efficacy data described as strong, especially for FT819 in lupus nephritis. Phase II is underway, with early results described as promising and a 30%-40% CRR targeted, alongside plans for broad future expansion.